drugset / Trial / NCT00304655

Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)

NCT00304655

Phase 4 Completed 300 enrolled Korea Otsuka Pharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to prove safety and efficacy of aripiprazole.

Timeline

Start
2004-07
Primary completion
2006-05
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 10 mg
Subject Aripiprazole Other / unclassified 15 mg
Subject Aripiprazole Other / unclassified 30 mg